Replies to post #15582 on Synaptogenix Inc (SNPX)

[runncoach]

There are actually more but its for 2 primary aspects of the disease is what i was trying to say.

For example there have been other drugs such as bryostatin which have shown to decrease some of those biomarkers. Conversely I'm sure some would argue there could be different biomarkers used for the same 2 aspects (neuroinflammation and neurodegeneration). In some ways it could be like bryostatin which increases pkce, using low pkce levels as a marker for neurodegeneration but that wouldn't be proof of cognitive improvement.

Over the next decade its going to be interesting to see which biomarkers can potentially be proven and recognized by the FDA when running these clinical trials. Certainly not saying anything negative about Sava. Just sayin it's gonna take some cognitive testing before those biomarkers will be accepted in my opinion

[runncoach]

I guess another way to say it that there are at least a dozen completely different biological mechanisms researchers have shown are deficient or lacking in AD patients that bryostatin improves. What if we designed a trial and measured these 12+ functions as markers? Still wouldn't mean much until you see cognitive improvement. I am very much looking forward to SAVA's confirmatory trial this summer. I personally think they are doing things the right way.